{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:34:05Z","timestamp":1791866045820,"version":"4.3.4"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04596-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:17:55Z","timestamp":1761556675000},"page":"4737-4754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy"],"prefix":"10.1007","volume":"399","author":[{"given":"Shaheen","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufi","family":"Nazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukund","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Tanweer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozair","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"4596_CR1","doi-asserted-by":"publisher","unstructured":"Akhter MH, Ahmad I, Alshahrani MY, Al-Harbi AI, Khalilullah H, Afzal O, Altamimi ASA, Najib Ullah SNM, Ojha A, Karim S (2022) Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels 8(2):82. https:\/\/doi.org\/10.3390\/GELS8020082","DOI":"10.3390\/GELS8020082"},{"issue":"12","key":"4596_CR2","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/PHARMACEUTICS14122728","volume":"14","author":"HO Alsaab","year":"2022","unstructured":"Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, Alshehri BY, Saleh MA, Alshehri FS, Algarni MA, Almugaiteeb T, Uddin MN, Alzhrani RM (2022) PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics 14(12):2728. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14122728","journal-title":"Pharmaceutics"},{"issue":"8","key":"4596_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/J.JBC.2022.102247","volume":"298","author":"C Arter","year":"2022","unstructured":"Arter C, Trask L, Ward S, Yeoh S, Bayliss R (2022) Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. J Biol Chem 298(8):102247. https:\/\/doi.org\/10.1016\/J.JBC.2022.102247","journal-title":"J Biol Chem"},{"issue":"10","key":"4596_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2023.E20657","volume":"9","author":"M Bahrami Parsa","year":"2023","unstructured":"Bahrami Parsa M, Tafvizi F, Chaleshi V, Ebadi M (2023) Preparation, characterization, and co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer activities. Heliyon 9(10):e20657. https:\/\/doi.org\/10.1016\/J.HELIYON.2023.E20657","journal-title":"Heliyon"},{"issue":"2","key":"4596_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0167-4838(87)90112-9","volume":"916","author":"M Bajaj","year":"1987","unstructured":"Bajaj M, Waterfield MD, Schlessinger J, Taylor WR, Blundell T (1987) On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim Biophys Acta 916(2):220\u2013226. https:\/\/doi.org\/10.1016\/0167-4838(87)90112-9","journal-title":"Biochim Biophys Acta"},{"key":"4596_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.BIOMATERIALS.2016.05.041","volume":"101","author":"AM Brinkman","year":"2016","unstructured":"Brinkman AM, Chen G, Wang Y, Hedman CJ, Sherer NM, Havighurst TC, Gong S, Xu W (2016) Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 101:20\u201331. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2016.05.041","journal-title":"Biomaterials"},{"key":"4596_CR7","doi-asserted-by":"publisher","unstructured":"Bromma K, Chithrani DB (2020) Advances in gold nanoparticle-based combined cancer therapy. Nanomaterials 10(9):1671. https:\/\/doi.org\/10.3390\/NANO10091671","DOI":"10.3390\/NANO10091671"},{"issue":"15","key":"4596_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/J.ADDR.2008.08.005","volume":"60","author":"JD Byrne","year":"2008","unstructured":"Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615\u20131626. https:\/\/doi.org\/10.1016\/J.ADDR.2008.08.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"4596_CR9","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/SJ.ONC.1210983","volume":"27","author":"CQ Cai","year":"2008","unstructured":"Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I, Lee P (2008) Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27(22):3201\u20133210. https:\/\/doi.org\/10.1038\/SJ.ONC.1210983","journal-title":"Oncogene"},{"issue":"12","key":"4596_CR10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2217\/NNM.12.169","volume":"7","author":"E Casals","year":"2012","unstructured":"Casals E, Puntes VF (2012) Inorganic nanoparticle biomolecular corona: formation, evolution and biological impact. Nanomedicine 7(12):1917\u20131930. https:\/\/doi.org\/10.2217\/NNM.12.169","journal-title":"Nanomedicine"},{"key":"4596_CR11","doi-asserted-by":"publisher","unstructured":"Casta\u00f1eda-Gonz\u00e1lez JP, Chaves JJ, Parra-Medina R (2022) Multiple mutations in the EGFR gene in lung cancer: a systematic review. Transl Lung Cancer Res\u00a011(10):2148\u20132163. https:\/\/doi.org\/10.21037\/TLCR-22-235\/COIF","DOI":"10.21037\/TLCR-22-235\/COIF"},{"issue":"1","key":"4596_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-023-01865-0\/TABLES\/15","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R (2023) Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer 22(1):1\u2013103. https:\/\/doi.org\/10.1186\/S12943-023-01865-0\/TABLES\/15","journal-title":"Mol Cancer"},{"key":"4596_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/J.BIOACTMAT.2025.07.033","volume":"53","author":"Y Chen","year":"2025","unstructured":"Chen Y, Sun H, Li Y, Han X, Yang Y, Chen Z, Zhao X, Qian Y, Liu X, Zhou F, Bai J, Qiao Y (2025) Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Bioact Mater 53:591\u2013629. https:\/\/doi.org\/10.1016\/J.BIOACTMAT.2025.07.033","journal-title":"Bioact Mater"},{"key":"4596_CR14","unstructured":"Chidharla A, Parsi M, Kasi A (2023) Cetuximab. StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459293\/"},{"issue":"2","key":"4596_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3892\/IJO.2013.2195","volume":"44","author":"SS Chung","year":"2014","unstructured":"Chung SS, Giehl N, Wu Y, Vadgama JV (2014) STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 44(2):403\u2013411. https:\/\/doi.org\/10.3892\/IJO.2013.2195","journal-title":"Int J Oncol"},{"issue":"4","key":"4596_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/THEONCOLOGIST.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8(4):303\u2013306. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.8-4-303","journal-title":"Oncologist"},{"issue":"7","key":"4596_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/THEONCOLOGIST.10-7-461","volume":"10","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Chen Y-F, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10(7):461\u2013466. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.10-7-461","journal-title":"Oncologist"},{"issue":"9","key":"4596_CR18","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1021\/NN201822B","volume":"5","author":"M Creixell","year":"2011","unstructured":"Creixell M, Boh\u00f3rquez AC, Torres-Lugo M, Rinaldi C (2011) EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano 5(9):7124\u20137129. https:\/\/doi.org\/10.1021\/NN201822B","journal-title":"ACS Nano"},{"key":"4596_CR19","doi-asserted-by":"publisher","unstructured":"Crintea A, Dutu AG, Samasca G, Florian IA, Lupan I, Craciun AM (2021) The nanosystems involved in treating lung cancer. Life 11(7):682. https:\/\/doi.org\/10.3390\/LIFE11070682","DOI":"10.3390\/LIFE11070682"},{"key":"4596_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.JCONREL.2016.11.015","volume":"244","author":"F Danhier","year":"2016","unstructured":"Danhier F (2016) To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244:108\u2013121. https:\/\/doi.org\/10.1016\/J.JCONREL.2016.11.015","journal-title":"J Control Release"},{"key":"4596_CR21","doi-asserted-by":"publisher","unstructured":"de Sousa Victor R, da Cunha Santos AM, da C., de Sousa BV et al (2020). A review on chitosan\u2019s uses as biomaterial: tissue engineering, drug delivery systems and cancer treatment. Materials\u00a013(21):4995. https:\/\/doi.org\/10.3390\/MA13214995","DOI":"10.3390\/MA13214995"},{"issue":"1","key":"4596_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/S11095-008-9697-X","volume":"26","author":"P Decuzzi","year":"2009","unstructured":"Decuzzi P, Pasqualini R, Arap W, Ferrari M (2009) Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26(1):235\u2013243. https:\/\/doi.org\/10.1007\/S11095-008-9697-X","journal-title":"Pharm Res"},{"issue":"15","key":"4596_CR23","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/S40265-017-0811-4","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED (2017) Neratinib: first global approval. Drugs 77(15):1695\u20131704. https:\/\/doi.org\/10.1007\/S40265-017-0811-4","journal-title":"Drugs"},{"key":"4596_CR24","doi-asserted-by":"publisher","unstructured":"Derynck R, Roberts AB, Winkler ME, Chen EY, Goeddel DV (1984) Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell\u00a038(1):287\u2013297. https:\/\/doi.org\/10.1016\/0092-8674(84)90550-6","DOI":"10.1016\/0092-8674(84)90550-6"},{"key":"4596_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.1048166","author":"B Doleschal","year":"2022","unstructured":"Doleschal B, Petzer A, Rumpold H (2022) Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Front Oncol. https:\/\/doi.org\/10.3389\/FONC.2022.1048166","journal-title":"Front Oncol"},{"issue":"25","key":"4596_CR26","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/ONC.2014.291","volume":"34","author":"W Du","year":"2015","unstructured":"Du W, Elemento O (2015) Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene 34(25):3215\u20133225. https:\/\/doi.org\/10.1038\/ONC.2014.291","journal-title":"Oncogene"},{"issue":"2","key":"4596_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/J.XINN.2021.100103","volume":"2","author":"X Du","year":"2021","unstructured":"Du X, Yang B, An Q, Assaraf YG, Cao X, Xia J (2021) Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (Camb) 2(2):100103. https:\/\/doi.org\/10.1016\/J.XINN.2021.100103","journal-title":"Innovation (Camb)"},{"issue":"13","key":"4596_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/S40265-013-0111-6","volume":"73","author":"RT Dungo","year":"2013","unstructured":"Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs 73(13):1503\u20131515. https:\/\/doi.org\/10.1007\/S40265-013-0111-6","journal-title":"Drugs"},{"key":"4596_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-642-54490-3_10","volume":"201","author":"TJ Ettrich","year":"2014","unstructured":"Ettrich TJ, Seufferlein T (2014) Regorafenib. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer 201:185\u2013196. https:\/\/doi.org\/10.1007\/978-3-642-54490-3_10","journal-title":"Progres Dans Les Recherches Sur Le Cancer"},{"key":"4596_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/J.IJBIOMAC.2018.05.121","volume":"117","author":"N Fathi","year":"2018","unstructured":"Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S (2018) STAT3 and apoptosis challenges in cancer. Int J Biol Macromol 117:993\u20131001. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2018.05.121","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4596_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L (2022) Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol 15(1):173. https:\/\/doi.org\/10.1186\/S13045-022-01391-4","journal-title":"J Hematol Oncol"},{"key":"4596_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/J.COLSURFB.2021.112305","volume":"211","author":"PD Ganthala","year":"2022","unstructured":"Ganthala PD, Alavala S, Chella N, Andugulapati SB, Bathini NB, Sistla R (2022) Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K\/AKT inhibition. Colloids Surf, B 211:112305. https:\/\/doi.org\/10.1016\/J.COLSURFB.2021.112305","journal-title":"Colloids Surf, B"},{"key":"4596_CR33","doi-asserted-by":"publisher","unstructured":"Gemmete JJ, Mukherji SK (2011) Panitumumab (Vectibix). AJNR: Am J Neuroradiol, 32(6):1002. https:\/\/doi.org\/10.3174\/AJNR.A2601","DOI":"10.3174\/AJNR.A2601"},{"key":"4596_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.ADDR.2018.07.007","volume":"130","author":"SK Golombek","year":"2018","unstructured":"Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 130:17\u201338. https:\/\/doi.org\/10.1016\/J.ADDR.2018.07.007","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4596_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/S40265-015-0533-4","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL (2016) Osimertinib: first global approval. Drugs 76(2):263\u2013273. https:\/\/doi.org\/10.1007\/S40265-015-0533-4","journal-title":"Drugs"},{"issue":"12","key":"4596_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/J.TIPS.2019.10.004","volume":"40","author":"S Guardiola","year":"2019","unstructured":"Guardiola S, Varese M, S\u00e1nchez-Navarro M, Giralt E (2019) A third shot at EGFR: New opportunities in cancer therapy. Trends Pharmacol Sci 40(12):941\u2013955. https:\/\/doi.org\/10.1016\/J.TIPS.2019.10.004","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"4596_CR37","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1074\/JBC.272.5.2927","volume":"272","author":"Su Huang","year":"1997","unstructured":"Huang Su, Huang HJ, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272(5):2927\u20132935. https:\/\/doi.org\/10.1074\/JBC.272.5.2927","journal-title":"J Biol Chem"},{"issue":"3","key":"4596_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","volume":"109","author":"M Huse","year":"2002","unstructured":"Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109(3):275\u2013282. https:\/\/doi.org\/10.1016\/S0092-8674(02)00741-9","journal-title":"Cell"},{"key":"4596_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTRV.2022.102466","volume":"110","author":"KK Iyer","year":"2022","unstructured":"Iyer KK, van Erp NP, Tauriello DVF, Verheul HMW, Poel D (2022) Lost in translation: revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treat Rev 110:102466. https:\/\/doi.org\/10.1016\/J.CTRV.2022.102466","journal-title":"Cancer Treat Rev"},{"key":"4596_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPX.2024.100281","volume":"8","author":"P Jarmila","year":"2024","unstructured":"Jarmila P, Veronika M, Peter M (2024) Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles. International Journal of Pharmaceutics: X 8:100281. https:\/\/doi.org\/10.1016\/J.IJPX.2024.100281","journal-title":"International Journal of Pharmaceutics: X"},{"issue":"8","key":"4596_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMOA044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib. N Engl J Med 352(8):786\u2013792. https:\/\/doi.org\/10.1056\/NEJMOA044238. (\/ASSET\/83826452-B06B-447B-A022-7C7D2651A2B0\/ASSETS\/IMAGES\/LARGE\/NEJMOA044238_F3.JPG)","journal-title":"N Engl J Med"},{"issue":"3","key":"4596_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0167-4838(92)90245-9","volume":"1120","author":"H Koide","year":"1992","unstructured":"Koide H, Muto Y, Kasai H, Kohri K, Hoshi K, Takahashi S, Tsukumo K, Sasaki T, Oka T, Miyake T, Fuwa T, Kohda D, Inagaki F, Miyazawa T, Yokoyama S (1992) A site-directed mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim Biophys Acta 1120(3):257\u2013261. https:\/\/doi.org\/10.1016\/0167-4838(92)90245-9","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"4596_CR43","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1200\/JCO.2007.12.1178","volume":"26","author":"A Kumar","year":"2008","unstructured":"Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology 26(10):1742\u20131751. https:\/\/doi.org\/10.1200\/JCO.2007.12.1178","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"4596_CR44","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.2147\/IJN.S65990","volume":"9","author":"S Kuroda","year":"2014","unstructured":"Kuroda S, Tam J, Roth JA, Sokolov K, Ramesh R (2014) EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2\/M cell-cycle arrest and inducing DNA damage. Int J Nanomed 9(1):3825\u20133839. https:\/\/doi.org\/10.2147\/IJN.S65990","journal-title":"Int J Nanomed"},{"issue":"3","key":"4596_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000467387","volume":"12","author":"E Laakmann","year":"2017","unstructured":"Laakmann E, M\u00fcller V, Schmidt M, Witzel I (2017) Systemic treatment options for HER2-positive breast cancer patients with brain metastases beyond trastuzumab: a literature review. Breast Care 12(3):168\u2013171. https:\/\/doi.org\/10.1159\/000467387","journal-title":"Breast Care"},{"key":"4596_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2021.103225","volume":"159","author":"J Lai-Kwon","year":"2021","unstructured":"Lai-Kwon J, Tiu C, Pal A, Khurana S, Minchom A (2021) Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Crit Rev Oncol Hematol 159:103225. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2021.103225","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"4596_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/J.JCONREL.2011.09.063","volume":"161","author":"T Lammers","year":"2012","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release\u202f: Official Journal of the Controlled Release Society 161(2):175\u2013187. https:\/\/doi.org\/10.1016\/J.JCONREL.2011.09.063","journal-title":"Journal of Controlled Release : Official Journal of the Controlled Release Society"},{"issue":"10","key":"4596_CR48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/S40265-020-01340-W","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A (2020) Tucatinib: first approval. Drugs 80(10):1033\u20131038. https:\/\/doi.org\/10.1007\/S40265-020-01340-W","journal-title":"Drugs"},{"issue":"4","key":"4596_CR49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/J.CELL.2012.03.031","volume":"149","author":"MJ Lee","year":"2012","unstructured":"Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB (2012) Sequential application of anti-cancer drugs enhances cell death by re-wiring apoptotic signaling networks. Cell 149(4):780. https:\/\/doi.org\/10.1016\/J.CELL.2012.03.031","journal-title":"Cell"},{"issue":"2","key":"4596_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/EMBOJ\/16.2.281","volume":"16","author":"MA Lemmon","year":"1997","unstructured":"Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, Schlessinger J (1997) Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 16(2):281\u2013294. https:\/\/doi.org\/10.1093\/EMBOJ\/16.2.281","journal-title":"EMBO J"},{"issue":"3","key":"4596_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMOA2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, P\u00e9rol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, J\u00e4nne PA (2022) Trastuzumab deruxtecan in HER2 -mutant non\u2013small-cell lung cancer. N Engl J Med 386(3):241\u2013251. https:\/\/doi.org\/10.1056\/NEJMOA2112431. (\/SUPPL_FILE\/NEJMOA2112431_DATA-SHARING.PDF)","journal-title":"N Engl J Med"},{"key":"4596_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/S12964-023-01082-8","author":"Y Li","year":"2023","unstructured":"Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P, Yang S, Zhu L, Guo S, Zhao X, Tian Y, Shen H, Lin F (2023) Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Commun Signal. https:\/\/doi.org\/10.1186\/S12964-023-01082-8","journal-title":"Cell Commun Signal"},{"key":"4596_CR53","doi-asserted-by":"publisher","unstructured":"Litwack G (2018) Enzymes. Human Biochem\u00a095\u2013129. https:\/\/doi.org\/10.1016\/B978-0-12-383864-3.00005-3","DOI":"10.1016\/B978-0-12-383864-3.00005-3"},{"key":"4596_CR54","doi-asserted-by":"publisher","unstructured":"Lombardo D, Kiselev MA (2022) Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics 14(3):543. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14030543","DOI":"10.3390\/PHARMACEUTICS14030543"},{"issue":"21","key":"4596_CR55","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMOA040938\/SUPPL_FILE\/NEJMOA040938_APPENDIX.PDF","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMOA040938\/SUPPL_FILE\/NEJMOA040938_APPENDIX.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"4596_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/S10549-015-3578-X","volume":"153","author":"A Madrid-Paredes","year":"2015","unstructured":"Madrid-Paredes A, Ca\u00f1adas-Garre M, S\u00e1nchez-Pozo A, Calleja-Hern\u00e1ndez M\u00c1 (2015) Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. Breast Cancer Res Treat 153(3):493\u2013505. https:\/\/doi.org\/10.1007\/S10549-015-3578-X. (\/METRICS)","journal-title":"Breast Cancer Res Treat"},{"key":"4596_CR57","doi-asserted-by":"publisher","unstructured":"Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3(3):1377\u20131397. https:\/\/doi.org\/10.3390\/POLYM3031377","DOI":"10.3390\/POLYM3031377"},{"issue":"5600","key":"4596_CR58","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/SCIENCE.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912\u20131934. https:\/\/doi.org\/10.1126\/SCIENCE.1075762","journal-title":"Science"},{"issue":"17","key":"4596_CR59","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/S40265-021-01632-9","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A (2021) Mobocertinib: first approval. Drugs 81(17):2069\u20132074. https:\/\/doi.org\/10.1007\/S40265-021-01632-9","journal-title":"Drugs"},{"key":"4596_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Pandiella A, Vargas-Castrill\u00f3n E, D\u00edaz-Rodr\u00edguez E, Iglesias-Hernang\u00f3mez T, Mart\u00ednez Cano C, Fern\u00e1ndez-Cuesta I, Winkow E, Perell\u00f3 MF (2024) Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol 198:104355. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2024.104355","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"4596_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/S40259-016-0162-9","volume":"30","author":"S Maximiano","year":"2016","unstructured":"Maximiano S, Magalh\u00e3es P, Guerreiro MP, Morgado M (2016) Trastuzumab in the treatment of breast cancer. BioDrugs 30(2):75\u201386. https:\/\/doi.org\/10.1007\/S40259-016-0162-9. (\/METRICS)","journal-title":"BioDrugs"},{"issue":"2","key":"4596_CR62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.CARBPOL.2012.12.032","volume":"93","author":"S Maya","year":"2013","unstructured":"Maya S, Kumar LG, Sarmento B, Sanoj Rejinold N, Menon D, Nair SV, Jayakumar R (2013) Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym 93(2):661\u2013669. https:\/\/doi.org\/10.1016\/J.CARBPOL.2012.12.032","journal-title":"Carbohydr Polym"},{"key":"4596_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.COLSURFB.2017.07.038","volume":"159","author":"M Mir","year":"2017","unstructured":"Mir M, Ahmed N, Rehman A (2017) Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf, B 159:217\u2013231. https:\/\/doi.org\/10.1016\/J.COLSURFB.2017.07.038","journal-title":"Colloids Surf, B"},{"issue":"10","key":"4596_CR64","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMOA0810699\/SUPPL_FILE\/NEJM_MOK_947SA1.PDF","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947\u2013957. https:\/\/doi.org\/10.1056\/NEJMOA0810699\/SUPPL_FILE\/NEJM_MOK_947SA1.PDF","journal-title":"N Engl J Med"},{"key":"4596_CR65","doi-asserted-by":"publisher","unstructured":"Moodley T, Singh M (2021) Current stimuli-responsive mesoporous silica nanoparticles for cancer therapy. Pharmaceutics 13(1):71. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13010071","DOI":"10.3390\/PHARMACEUTICS13010071"},{"key":"4596_CR66","doi-asserted-by":"publisher","unstructured":"Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, Shah NJ, Yaffe MB, Hammond PT (2014) A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Science Signaling\u00a07(325). https:\/\/doi.org\/10.1126\/SCISIGNAL.2005261","DOI":"10.1126\/SCISIGNAL.2005261"},{"key":"4596_CR67","unstructured":"Murphrey, M. B., Quaim, L., Rahimi, N., & Varacallo, M. A. (2023). Biochemistry, epidermal growth factor receptor. StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482459\/"},{"key":"4596_CR68","doi-asserted-by":"publisher","unstructured":"Nan X, Xie C, Yu X, Liu J (2017) EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 8(43):75712\u201375726. https:\/\/doi.org\/10.18632\/ONCOTARGET.20095","DOI":"10.18632\/ONCOTARGET.20095"},{"issue":"12","key":"4596_CR69","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1021\/ACS.MOLPHARMACEUT.5B00642\/SUPPL_FILE\/MP5B00642_SI_001.PDF","volume":"12","author":"AV Nascimento","year":"2015","unstructured":"Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM (2015) Combinatorial-designed epidermal growth factor receptor-targeted chitosan nanoparticles for encapsulation and delivery of lipid-modified platinum derivatives in wild-type and resistant non-small-cell lung cancer cells. Mol Pharm 12(12):4466\u20134477. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.5B00642\/SUPPL_FILE\/MP5B00642_SI_001.PDF","journal-title":"Mol Pharm"},{"issue":"3","key":"4596_CR70","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/APB.2015.043","volume":"5","author":"N Naseri","year":"2015","unstructured":"Naseri N, Valizadeh H, Zakeri-Milani P (2015) Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 5(3):305\u2013313. https:\/\/doi.org\/10.15171\/APB.2015.043","journal-title":"Adv Pharm Bull"},{"issue":"16","key":"4596_CR71","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1073\/PNAS.91.16.7727","volume":"91","author":"R Nishikawa","year":"1994","unstructured":"Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91(16):7727\u20137731. https:\/\/doi.org\/10.1073\/PNAS.91.16.7727","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4596_CR72","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/10717544.2017.1384862","volume":"24","author":"XL Ni","year":"2017","unstructured":"Ni XL, Chen LX, Zhang H, Yang B, Xu S, Wu M, Liu J, Yang LL, Chen Y, Fu SZ, Wu JB (2017) In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer. Drug Delivery 24(1):1501\u20131512. https:\/\/doi.org\/10.1080\/10717544.2017.1384862","journal-title":"Drug Delivery"},{"issue":"2","key":"4596_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/PHARMACEUTICS16020205\/S1","volume":"16","author":"CD Ni\u0163u","year":"2024","unstructured":"Ni\u0163u CD, Mernea M, Vlasceanu RI, Voicu-Balasea B, Badea MA, Raduly FM, R\u0103di\u0163oiu V, R\u0103di\u0163oiu A, Avram S, Mihailescu DF, Voinea IC, Stan MS (2024) Biomedical promise of sustainable microwave-engineered symmetric curcumin derivatives. Pharmaceutics 16(2):205. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16020205\/S1","journal-title":"Pharmaceutics"},{"key":"4596_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2022.E09394","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W (2022) Liposomes: structure, composition, types, and clinical applications. Heliyon. https:\/\/doi.org\/10.1016\/J.HELIYON.2022.E09394","journal-title":"Heliyon"},{"issue":"1","key":"4596_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/OXFORDJOURNALS.JBCHEM.A021718","volume":"122","author":"M Odaka","year":"1997","unstructured":"Odaka M, Kohda D, Lax I, Schlessinger J, Inagaki F (1997) Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. J Biochem 122(1):116\u2013121. https:\/\/doi.org\/10.1093\/OXFORDJOURNALS.JBCHEM.A021718","journal-title":"J Biochem"},{"issue":"6","key":"4596_CR76","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","volume":"110","author":"H Ogiso","year":"2002","unstructured":"Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110(6):775\u2013787. https:\/\/doi.org\/10.1016\/S0092-8674(02)00963-7","journal-title":"Cell"},{"issue":"36","key":"4596_CR77","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/PNAS.0405220101\/SUPPL_FILE\/05220TABLE5.XLS","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306\u201313311. https:\/\/doi.org\/10.1073\/PNAS.0405220101\/SUPPL_FILE\/05220TABLE5.XLS","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"4596_CR78","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/02652048.2018.1453560","volume":"35","author":"J Patel","year":"2018","unstructured":"Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A (2018) Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul 35(2):204\u2013217. https:\/\/doi.org\/10.1080\/02652048.2018.1453560. (;CTYPE:STRING:JOURNAL)","journal-title":"J Microencapsul"},{"issue":"12","key":"4596_CR79","doi-asserted-by":"publisher","first-page":"9480","DOI":"10.1021\/NN202410F","volume":"5","author":"XH Peng","year":"2011","unstructured":"Peng XH, Wang Y, Huang D, Wang Y, Shin HJ, Chen Z, Spewak MB, Mao H, Wang X, Wang Y, Chen Z, Nie S, Shin DM (2011) Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 5(12):9480\u20139493. https:\/\/doi.org\/10.1021\/NN202410F","journal-title":"ACS Nano"},{"key":"4596_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/POLYM14122510","author":"S Perumal","year":"2022","unstructured":"Perumal S, Atchudan R, Lee W (2022) A review of polymeric micelles and their applications. Polymers. https:\/\/doi.org\/10.3390\/POLYM14122510","journal-title":"Polymers"},{"key":"4596_CR81","doi-asserted-by":"publisher","unstructured":"Qian, J., Guo, Y., Xu, Y., Wang, X., Chen, J., & Wu, X. (2023). Combination of micelles and liposomes as a promising drug delivery system: a review. Drug Delivery and Translational Research 2023 13:11, 13(11), 2767\u20132789. https:\/\/doi.org\/10.1007\/S13346-023-01368-X","DOI":"10.1007\/S13346-023-01368-X"},{"issue":"Suppl 8","key":"4596_CR82","doi-asserted-by":"publisher","first-page":"viii7","DOI":"10.1093\/NEUONC\/NOU232","volume":"16","author":"DA Reardon","year":"2014","unstructured":"Reardon DA, Wen PY, Mellinghoff IK (2014) Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro-Oncol 16(Suppl 8):viii7\u2013viii13. https:\/\/doi.org\/10.1093\/NEUONC\/NOU232","journal-title":"Neuro-Oncol"},{"key":"4596_CR83","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/J.PHRS.2018.11.014","volume":"139","author":"R Roskoski","year":"2019","unstructured":"Roskoski R (2019) Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 139:395\u2013411. https:\/\/doi.org\/10.1016\/J.PHRS.2018.11.014","journal-title":"Pharmacol Res"},{"issue":"12","key":"4596_CR84","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008209720526","volume":"8","author":"B Rude Voldborg","year":"1997","unstructured":"Rude Voldborg B, Damstrup L, Spang-Thomsen M, Skovgaard Poulsen H (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology\u202f: Official Journal of the European Society for Medical Oncology 8(12):1197\u20131206. https:\/\/doi.org\/10.1023\/A:1008209720526","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"5","key":"4596_CR85","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1166\/JBN.2010.1149","volume":"6","author":"A Schroeter","year":"2010","unstructured":"Schroeter A, Engelbrecht T, Neubert RHH, Goebel ASB (2010) New nanosized technologies for dermal and transdermal drug delivery. A review. J Biomed Nanotechnol 6(5):511\u2013528. https:\/\/doi.org\/10.1166\/JBN.2010.1149","journal-title":"J Biomed Nanotechnol"},{"issue":"3","key":"4596_CR86","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/J.CLLC.2019.12.003","volume":"21","author":"R Shah","year":"2020","unstructured":"Shah R, Lester JF (2020) Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non\u2013small-cell lung cancer: a clash of the generations. Clin Lung Cancer 21(3):e216\u2013e228. https:\/\/doi.org\/10.1016\/J.CLLC.2019.12.003","journal-title":"Clin Lung Cancer"},{"key":"4596_CR87","doi-asserted-by":"publisher","unstructured":"Sharma B, Singh VJ, Chawla PA (2021) Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress. Bioorg Chem 116. https:\/\/doi.org\/10.1016\/J.BIOORG.2021.105393","DOI":"10.1016\/J.BIOORG.2021.105393"},{"issue":"5","key":"4596_CR88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/JNCI\/DJI055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339\u2013346. https:\/\/doi.org\/10.1093\/JNCI\/DJI055","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"4596_CR89","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/S40265-018-1028-X","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M (2018) Dacomitinib: first global approval. Drugs 78(18):1947\u20131953. https:\/\/doi.org\/10.1007\/S40265-018-1028-X","journal-title":"Drugs"},{"issue":"3","key":"4596_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/S40265-024-01998-6","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M (2024) Capivasertib: first approval. Drugs 84(3):337. https:\/\/doi.org\/10.1007\/S40265-024-01998-6","journal-title":"Drugs"},{"key":"4596_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS17091440","author":"PI Siafaka","year":"2016","unstructured":"Siafaka PI, \u00dcst\u00fcnda\u011f Okur N, Karavas E, Bikiaris DN (2016) Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS17091440","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4596_CR92","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101\/ASSET\/5945ED79-B9B0-4E11-A1F0-156D1C26C918\/ASSETS\/IMAGES\/LARGE\/NEJM200103153441101_T4.JPG","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101\/ASSET\/5945ED79-B9B0-4E11-A1F0-156D1C26C918\/ASSETS\/IMAGES\/LARGE\/NEJM200103153441101_T4.JPG","journal-title":"N Engl J Med"},{"issue":"11","key":"4596_CR93","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/J.ADDR.2008.03.012","volume":"60","author":"II Slowing","year":"2008","unstructured":"Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60(11):1278\u20131288. https:\/\/doi.org\/10.1016\/J.ADDR.2008.03.012","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4596_CR94","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.7150\/THNO.48662","volume":"11","author":"V Smidova","year":"2021","unstructured":"Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z (2021) Nanomedicine of tyrosine kinase inhibitors. Theranostics 11(4):1546\u20131567. https:\/\/doi.org\/10.7150\/THNO.48662","journal-title":"Theranostics"},{"issue":"23","key":"4596_CR95","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMOA1408440\/SUPPL_FILE\/NEJMOA1408440_DISCLOSURES.PDF","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) First-line crizotinib versus chemotherapy in ALK -positive lung cancer. N Engl J Med 371(23):2167\u20132177. https:\/\/doi.org\/10.1056\/NEJMOA1408440\/SUPPL_FILE\/NEJMOA1408440_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"4596_CR96","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/NTNO.19952","volume":"1","author":"L Song","year":"2017","unstructured":"Song L, Able S, Johnson E, Vallis KA (2017) Accumulation of111in-labelled egf-au-peg nanoparticles in egfr-positive tumours is enhanced by coadministration of targeting ligand. Nanotheranostics 1(3):232\u2013243. https:\/\/doi.org\/10.7150\/NTNO.19952","journal-title":"Nanotheranostics"},{"key":"4596_CR97","doi-asserted-by":"publisher","unstructured":"Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W.-C., Gray, J. E., \u2026 Ramalingam, S. S. (2018). Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer . New England Journal of Medicine, 378(2), 113\u2013125. https:\/\/doi.org\/10.1056\/NEJMOA1713137\/SUPPL_FILE\/NEJMOA1713137_DISCLOSURES.PDF","DOI":"10.1056\/NEJMOA1713137\/SUPPL_FILE\/NEJMOA1713137_DISCLOSURES.PDF"},{"key":"4596_CR98","unstructured":"Study details | docetaxel, cisplatin, and erlotinib hydrochloride in treating patients with stage I-III non-small cell lung cancer following surgery | ClinicalTrials.gov. (n.d.). Retrieved October 16, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT00254384?term=NCT00254384&rank=1"},{"key":"4596_CR99","unstructured":"Study details | niraparib and panitumumab in patients with advanced or metastatic colorectal cancer | ClinicalTrials.gov. (n.d.). Retrieved October 16, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT03983993?term=NCT03983993&rank=1"},{"key":"4596_CR100","unstructured":"Study details | osimertinib and necitumumab in treating patients with EGFR-mutant stage IV or recurrent non-small cell lung cancer who have progressed on a previous EGFR tyrosine kinase inhibitor | ClinicalTrials.gov. (n.d.). Retrieved October 16, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT02496663#more-information"},{"key":"4596_CR101","unstructured":"Study details | testing the combination of MLN0128 (TAK-228) and AZD9291 in advanced EGFR (epidermal growth factor receptor) mutation positive non-small cell lung cancer | ClinicalTrials.gov. (n.d.). Retrieved October 16, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT02503722?term=NCT02503722&rank=1"},{"issue":"1","key":"4596_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.PCCM.2022.10.001","volume":"1","author":"SY Sun","year":"2023","unstructured":"Sun SY (2023) Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors. Chinese Medical Journal Pulmonary and Critical Care Medicine 1(1):3\u201310. https:\/\/doi.org\/10.1016\/J.PCCM.2022.10.001","journal-title":"Chinese Medical Journal Pulmonary and Critical Care Medicine"},{"key":"4596_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.702445","volume":"12","author":"M Sun","year":"2021","unstructured":"Sun M, Wang T, Li L, Li X, Zhai Y, Zhang J, Li W (2021) The application of inorganic nanoparticles in molecular targeted cancer therapy: EGFR targeting. Front Pharmacol 12:702445. https:\/\/doi.org\/10.3389\/FPHAR.2021.702445. (\/BIBTEX)","journal-title":"Front Pharmacol"},{"key":"4596_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/939378","volume":"2014","author":"KB Sutradhar","year":"2014","unstructured":"Sutradhar KB, Amin MdL (2014) Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnology 2014:1\u201312. https:\/\/doi.org\/10.1155\/2014\/939378","journal-title":"ISRN Nanotechnology"},{"issue":"7","key":"4596_CR105","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/S40265-017-0742-0","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY (2017) Ribociclib: first global approval. Drugs 77(7):799\u2013807. https:\/\/doi.org\/10.1007\/S40265-017-0742-0","journal-title":"Drugs"},{"issue":"3","key":"4596_CR106","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/FON.14.249","volume":"11","author":"F Tan","year":"2015","unstructured":"Tan F, Shi Y, Wang Y, Ding L, Yuan X, Sun Y (2015) Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncology (London, England) 11(3):385\u2013397. https:\/\/doi.org\/10.2217\/FON.14.249","journal-title":"Future Oncology (London, England)"},{"issue":"30","key":"4596_CR107","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1039\/C7TB01370A","volume":"5","author":"J Tian","year":"2017","unstructured":"Tian J, Min Y, Rodgers Z, Au KM, Hagan CT, Zhang M, Roche K, Yang F, Wagner K, Wang AZ (2017) Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. Journal of Materials Chemistry B 5(30):6049\u20136057. https:\/\/doi.org\/10.1039\/C7TB01370A","journal-title":"Journal of Materials Chemistry B"},{"issue":"1","key":"4596_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/S10549-016-3866-0","volume":"158","author":"SR Tiwari","year":"2016","unstructured":"Tiwari SR, Mishra P, Raska P, Calhoun B, Abraham J, Moore H, Budd GT, Fanning A, Valente S, Stewart R, Grobmyer SR, Montero AJ (2016) Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab\/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat 158(1):189\u2013193. https:\/\/doi.org\/10.1007\/S10549-016-3866-0. (\/METRICS)","journal-title":"Breast Cancer Res Treat"},{"key":"4596_CR109","doi-asserted-by":"publisher","unstructured":"To, K. K. W., Wu, M., Tong, C. W. S., & Yan, W. (2020). Drug transporters in the development of multidrug resistance in colorectal cancer. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, 35\u201355. https:\/\/doi.org\/10.1016\/B978-0-12-819937-4.00002-9","DOI":"10.1016\/B978-0-12-819937-4.00002-9"},{"key":"4596_CR110","doi-asserted-by":"publisher","unstructured":"Tseng, C. L., Wang, T. W., Dong, G. C., Yueh-Hsiu Wu, S., Young, T. H., Shieh, M. J., Lou, P. J., & Lin, F. H. (2007). Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 28(27), 3996\u20134005. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2007.05.006","DOI":"10.1016\/J.BIOMATERIALS.2007.05.006"},{"issue":"2","key":"4596_CR111","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(90)90801-K","volume":"61","author":"A Ullrich","year":"1990","unstructured":"Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61(2):203\u2013212. https:\/\/doi.org\/10.1016\/0092-8674(90)90801-K","journal-title":"Cell"},{"key":"4596_CR112","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/J.IJBIOMAC.2018.10.181","volume":"122","author":"B Vaidya","year":"2019","unstructured":"Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, Kanabar D, Garcia JV, Mitragotri S, Muth A, Gupta V (2019) Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol 122:338\u2013347. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2018.10.181","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"4596_CR113","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/J.BBAMEM.2017.01.016","volume":"1859","author":"CC Valley","year":"2017","unstructured":"Valley CC, Lewis AK, Sachs JN (2017) Piecing it together: unraveling the elusive structure-function relationship in single-pass membrane receptors. Biochimica Et Biophysica Acta (BBA) - Biomembranes 1859(9):1398\u20131416. https:\/\/doi.org\/10.1016\/J.BBAMEM.2017.01.016","journal-title":"Biochimica Et Biophysica Acta (BBA) - Biomembranes"},{"issue":"11","key":"4596_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0206109","volume":"13","author":"V Venugopal","year":"2018","unstructured":"Venugopal V, Krishnan S, Palanimuthu VR, Sankarankutty S, Kalaimani JK, Karupiah S, Kit NS, Hock TT (2018) Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities. PLoS ONE 13(11):e0206109. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0206109","journal-title":"PLoS ONE"},{"issue":"19","key":"4596_CR115","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMOA1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Di\u00e9ras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMOA1209124","journal-title":"N Engl J Med"},{"key":"4596_CR116","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M (2018) Lapatinib. Recent results in cancer research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer 211:19\u201344. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_2","journal-title":"Progres Dans Les Recherches Sur Le Cancer"},{"key":"4596_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/SREP25468","author":"Y Wang","year":"2016","unstructured":"Wang Y, Huang HY, Yang L, Zhang Z, Ji H (2016) Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep. https:\/\/doi.org\/10.1038\/SREP25468","journal-title":"Sci Rep"},{"issue":"10","key":"4596_CR118","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1111\/CAS.13761","volume":"109","author":"L Wang","year":"2018","unstructured":"Wang L, Wang Q, Gao M, Fu L, Li Y, Quan H, Lou L (2018) STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. Cancer Sci 109(10):3305\u20133315. https:\/\/doi.org\/10.1111\/CAS.13761","journal-title":"Cancer Sci"},{"issue":"2","key":"4596_CR119","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/PROT.340220207","volume":"22","author":"CW Ward","year":"1995","unstructured":"Ward CW, Hoyne PA, Flegg RH (1995) Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 22(2):141\u2013153. https:\/\/doi.org\/10.1002\/PROT.340220207","journal-title":"Proteins"},{"key":"4596_CR120","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/ANNONC\/MDX703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10\u2013i19. https:\/\/doi.org\/10.1093\/ANNONC\/MDX703","journal-title":"Ann Oncol"},{"issue":"8","key":"4596_CR121","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/JPM11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J (2021) The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med 11(8):771. https:\/\/doi.org\/10.3390\/JPM11080771","journal-title":"J Pers Med"},{"key":"4596_CR122","doi-asserted-by":"publisher","unstructured":"Yamaoka T, Ohba M, Ohmori T (2017) Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci 18(11):2420. https:\/\/doi.org\/10.3390\/IJMS18112420","DOI":"10.3390\/IJMS18112420"},{"issue":"4","key":"4596_CR123","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1128\/MCB.8.4.1816-1820.1988","volume":"8","author":"H Yamazaki","year":"1988","unstructured":"Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8(4):1816\u20131820. https:\/\/doi.org\/10.1128\/MCB.8.4.1816-1820.1988","journal-title":"Mol Cell Biol"},{"issue":"11","key":"4596_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0025507","volume":"6","author":"T Yokoyama","year":"2011","unstructured":"Yokoyama T, Tam J, Kuroda S, Scott AW, Aaron J, Larson T, Shanker M, Correa AM, Kondo S, Roth JA, Sokolov K, Ramesh R (2011) EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS ONE 6(11):e25507. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0025507","journal-title":"PLoS ONE"},{"issue":"8","key":"4596_CR125","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246\/85140\/AM\/ANALYSIS-OF-MECHANISMS-OF-ACQUIRED-RESISTANCE-TO","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240\u20132247. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246\/85140\/AM\/ANALYSIS-OF-MECHANISMS-OF-ACQUIRED-RESISTANCE-TO","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4596_CR126","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.CCR.2006.12.017","volume":"11","author":"CH Yun","year":"2007","unstructured":"Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217\u2013227. https:\/\/doi.org\/10.1016\/J.CCR.2006.12.017","journal-title":"Cancer Cell"},{"issue":"10","key":"4596_CR127","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/J.CELLSIG.2007.06.023","volume":"19","author":"R Zandi","year":"2007","unstructured":"Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signalling 19(10):2013\u20132023. https:\/\/doi.org\/10.1016\/J.CELLSIG.2007.06.023","journal-title":"Cell Signalling"},{"key":"4596_CR128","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Cao, Y., Luo, S., Mukerabigwi, J. F., & Liu, M. (2016). Nanoparticles as drug delivery systems of combination therapy for cancer. Nanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials, 253\u2013280. https:\/\/doi.org\/10.1016\/B978-0-323-42863-7.00008-6","DOI":"10.1016\/B978-0-323-42863-7.00008-6"},{"key":"4596_CR129","doi-asserted-by":"publisher","unstructured":"Zheng, L., Luthra, R., Alvarez, H. A., San Lucas, F. A., Duose, D. Y., Wistuba, I. I., Fuller, G. N., Ballester, L. Y., Roy-Chowdhuri, S., Sweeney, K. J., Rashid, A., Yang, R. K., Chen, W., Liu, A., Wu, Y., Albarracin, C., Patel, K. P., Routbort, M. J., Sahin, A. A., \u2026 Chen, H. (2024). Intragenic EGFR::EGFR.E1E8 fusion (EGFRvIII) in 4331 solid tumors. Cancers, 16(1), 6. https:\/\/doi.org\/10.3390\/CANCERS16010006\/S1","DOI":"10.3390\/CANCERS16010006\/S1"},{"issue":"1","key":"4596_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.AJPS.2019.06.001","volume":"15","author":"X Zhou","year":"2019","unstructured":"Zhou X, Shi K, Hao Y, Yang C, Zha R, Yi C, Qian Z (2019) Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian J Pharm Sci 15(1):26. https:\/\/doi.org\/10.1016\/J.AJPS.2019.06.001","journal-title":"Asian J Pharm Sci"},{"key":"4596_CR131","doi-asserted-by":"publisher","unstructured":"Zhou, J., Ji, Q., & Li, Q. (2021). Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental & Clinical Cancer Research 2021 40:1, 40(1), 1\u201317. https:\/\/doi.org\/10.1186\/S13046-021-02130-2","DOI":"10.1186\/S13046-021-02130-2"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04596-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04596-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04596-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:14:58Z","timestamp":1775099698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04596-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4596"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04596-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}